Pfizer’s revenue reached $100 billion a few years ago, driven by its dominance in coronavirus treatments and prevention. In recent times, it’s faced a drop in that demand and losses of exclusivity ...
A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...
Pharmaceutical giant Pfizer PFE1.28%increase; green up pointing triangle and French vaccine maker Valneva VLA 0.29%increase; green up pointing triangle reported positive topline results from their ...
Pfizer has underperformed the market in each of the past three years. The stock is doing well of late as investors have been turning to safer investments amid uncertainty. Pfizer has been struggling ...
Pfizer said it will seek regulatory approval for a Lyme disease vaccine candidate despite failing a late-stage trial. Pfizer said not enough people contracted Lyme disease to be confident in the ...
Add Yahoo as a preferred source to see more of our stories on Google. A logo of Pfizer at the company’s booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, ...
Pfizer is eyeing an earlier use of its PARP inhibitor Talzenna after a positive phase 3 trial in metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 Talapro-3 trial met its primary ...
Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, a lackluster result as fewer-than-expected infections in the pivotal study made its potency ...
Pfizer’s CEO, Albert Bourla, Ph.D., has yet to top the $33 million in compensation that he earned on the coattails of megablockbuster COVID-19 sales in 2022, but a $27.6 million pay package after a ...
An experimental Lyme disease vaccine from Pfizer PFE0.40%increase; green up pointing triangle and Valneva VLA 0.93%increase; green up pointing triangle didn’t conclusively succeed in a large study, ...
A Lyme disease vaccine produced by Pfizer and Valneva was deemed 70 percent effective by the companies after they reviewed the results from a phase 3 trial. If approved by regulators, it would be the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results